14.14
price up icon4.12%   0.56
after-market アフターアワーズ: 14.50 0.36 +2.55%
loading
前日終値:
$13.58
開ける:
$13.24
24時間の取引高:
1.53M
Relative Volume:
3.20
時価総額:
$973.93M
収益:
$62.71M
当期純損益:
$-112.51M
株価収益率:
5.05
EPS:
2.8
ネットキャッシュフロー:
$-96.01M
1週間 パフォーマンス:
+12.40%
1か月 パフォーマンス:
-2.82%
6か月 パフォーマンス:
+68.13%
1年 パフォーマンス:
+52.54%
1日の値動き範囲:
Value
$13.11
$14.15
1週間の範囲:
Value
$12.48
$14.15
52週間の値動き範囲:
Value
$7.97
$17.70

Zymeworks Inc. Stock (ZYME) Company Profile

Name
名前
Zymeworks Inc.
Name
セクター
Healthcare (1176)
Name
電話
604-678-1388
Name
住所
1385 West 8th Avenue, Suite 540, Vancouver, BC
Name
職員
170
Name
Twitter
@ZymeworksInc
Name
次回の収益日
2024-10-31
Name
最新のSEC提出書
Name
ZYME's Discussions on Twitter

ZYME を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ZYME
Zymeworks Inc.
14.14 973.93M 62.71M -112.51M -96.01M -1.51
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.27 102.31B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
701.85 77.13B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
623.82 37.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.44 31.66B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.08 27.11B 3.30B -501.07M 1.03B -2.1146

Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-16 アップグレード JP Morgan Neutral → Overweight
2024-11-07 アップグレード Leerink Partners Market Perform → Outperform
2024-11-01 ダウングレード Wells Fargo Overweight → Equal Weight
2023-03-21 再開されました Wells Fargo Overweight
2023-01-04 繰り返されました H.C. Wainwright Neutral
2022-12-20 アップグレード Jefferies Hold → Buy
2022-11-01 ダウングレード H.C. Wainwright Buy → Neutral
2022-10-21 ダウングレード SVB Leerink Outperform → Mkt Perform
2022-10-04 再開されました Wells Fargo Overweight
2022-05-05 アップグレード Guggenheim Neutral → Buy
2022-03-15 開始されました Evercore ISI Outperform
2021-12-10 アップグレード SVB Leerink Mkt Perform → Outperform
2021-11-17 再開されました Guggenheim Neutral
2021-10-07 開始されました Jefferies Hold
2021-03-31 開始されました Credit Suisse Outperform
2021-02-25 ダウングレード SVB Leerink Outperform → Mkt Perform
2021-02-08 再開されました H.C. Wainwright Buy
2021-01-25 ダウングレード Citigroup Buy → Neutral
2020-09-29 再開されました JP Morgan Neutral
2020-08-06 開始されました SVB Leerink Outperform
2020-01-10 開始されました Wolfe Research Outperform
2019-12-09 開始されました JP Morgan Neutral
2019-11-25 開始されました H.C. Wainwright Buy
2019-11-20 開始されました Guggenheim Buy
2019-09-30 アップグレード Raymond James Outperform → Strong Buy
2019-08-30 開始されました Stifel Buy
2019-07-18 開始されました Deutsche Bank Buy
2018-05-11 アップグレード Barclays Underweight → Equal Weight
2018-03-19 開始されました Raymond James Outperform
すべてを表示

Zymeworks Inc. (ZYME) 最新ニュース

pulisher
Dec 20, 2024

Zymeworks (NYSE:ZYME) Shares Down 2.4%Here's Why - MarketBeat

Dec 20, 2024
pulisher
Dec 20, 2024

Y Intercept Hong Kong Ltd Has $147,000 Stock Holdings in Zymeworks Inc. (NYSE:ZYME) - MarketBeat

Dec 20, 2024
pulisher
Dec 19, 2024

Zymeworks (NYSE:ZYME) Stock Price Up 4.3% Following Analyst Upgrade - MarketBeat

Dec 19, 2024
pulisher
Dec 19, 2024

Wells Fargo & Company Issues Positive Forecast for Zymeworks (NYSE:ZYME) Stock Price - MarketBeat

Dec 19, 2024
pulisher
Dec 19, 2024

Zymeworks Stock: Prime Time Ziihera, Early-Stage Pipeline Ahead Of Schedule (NASDAQ:ZYME) - Seeking Alpha

Dec 19, 2024
pulisher
Dec 18, 2024

Wellington Management Group LLP Has $3.05 Million Position in Zymeworks Inc. (NYSE:ZYME) - MarketBeat

Dec 18, 2024
pulisher
Dec 17, 2024

JP Morgan Upgrades Zymeworks (ZYME) - MSN

Dec 17, 2024
pulisher
Dec 16, 2024

Zymeworks (NYSE:ZYME) Shares Gap UpHere's Why - MarketBeat

Dec 16, 2024
pulisher
Dec 16, 2024

Zymeworks (NYSE:ZYME) Upgraded at JPMorgan Chase & Co. - MarketBeat

Dec 16, 2024
pulisher
Dec 12, 2024

Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases - The Manila Times

Dec 12, 2024
pulisher
Dec 12, 2024

Zymeworks speeds up cancer drug development timeline - Investing.com

Dec 12, 2024
pulisher
Dec 12, 2024

Zymeworks Hosts R&D Day Highlighting Continued Clinical - GlobeNewswire

Dec 12, 2024
pulisher
Dec 12, 2024

Zymeworks Accelerates Cancer Drug Pipeline, Unveils Breakthrough Autoimmune Program 18 Months Ahead of Schedule - StockTitan

Dec 12, 2024
pulisher
Dec 12, 2024

Zymeworks Inc. (NYSE:ZYME) Shares Sold by Point72 Asset Management L.P. - MarketBeat

Dec 12, 2024
pulisher
Dec 12, 2024

Zymeworks adjusts non-employee director pay By Investing.com - Investing.com Canada

Dec 12, 2024
pulisher
Dec 11, 2024

Zymeworks adjusts non-employee director pay - Investing.com

Dec 11, 2024
pulisher
Dec 06, 2024

Jacobs Levy Equity Management Inc. Sells 129,088 Shares of Zymeworks Inc. (NYSE:ZYME) - MarketBeat

Dec 06, 2024
pulisher
Dec 06, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $19.13 Million Holdings in Zymeworks Inc. (NYSE:ZYME) - MarketBeat

Dec 06, 2024
pulisher
Dec 05, 2024

Zymeworks Inc. (NYSE:ZYME) is Redmile Group LLC's 6th Largest Position - MarketBeat

Dec 05, 2024
pulisher
Dec 03, 2024

Zymeworks Inc. (NYSE:ZYME) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat

Dec 03, 2024
pulisher
Nov 29, 2024

Vestal Point Capital LP Boosts Stake in Zymeworks Inc. (NYSE:ZYME) - MarketBeat

Nov 29, 2024
pulisher
Nov 25, 2024

Bloom Burton Estimates Zymeworks FY2024 Earnings - MarketBeat

Nov 25, 2024
pulisher
Nov 22, 2024

HC Wainwright Reaffirms Neutral Rating for Zymeworks (NYSE:ZYME) - MarketBeat

Nov 22, 2024
pulisher
Nov 22, 2024

In-Depth Examination Of 9 Analyst Recommendations For Zymeworks - Benzinga

Nov 22, 2024
pulisher
Nov 22, 2024

FDA approves cancer drug developed by B.C.'s Zymeworks - Head Topics

Nov 22, 2024
pulisher
Nov 21, 2024

Rare milestone for Canadian biotech as Zymeworks-developed drug gets FDA approval - The Globe and Mail

Nov 21, 2024
pulisher
Nov 21, 2024

FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework - Benzinga

Nov 21, 2024
pulisher
Nov 21, 2024

Zymeworks to Showcase Innovations at Investor Conferences - TipRanks

Nov 21, 2024
pulisher
Nov 21, 2024

Zymeworks Announces Participation in Upcoming Investor Conferences - The Manila Times

Nov 21, 2024
pulisher
Nov 21, 2024

Zymeworks to Present at Major Healthcare Conferences, Announces R&D Day for Pipeline Updates | ZYME Stock News - StockTitan

Nov 21, 2024
pulisher
Nov 21, 2024

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for - GlobeNewswire

Nov 21, 2024
pulisher
Nov 21, 2024

Zymeworks' Ziihera Wins FDA Approval: First Dual HER2 Cancer Drug Shows 52% Response Rate | ZYME Stock News - StockTitan

Nov 21, 2024
pulisher
Nov 20, 2024

Leerink Partners Upgrades Zymeworks (ZYME) - MSN

Nov 20, 2024
pulisher
Nov 15, 2024

Redmile Group, LLC Adjusts Stake in Zymeworks Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 12, 2024

Zymeworks stock soars to 52-week high, hits $17.29 By Investing.com - Investing.com Australia

Nov 12, 2024
pulisher
Nov 11, 2024

Zymeworks stock soars to 52-week high, hits $17.29 - Investing.com India

Nov 11, 2024
pulisher
Nov 11, 2024

Zymeworks (NYSE:ZYME) Stock Rating Upgraded by Leerink Partners - Defense World

Nov 11, 2024
pulisher
Nov 11, 2024

FY2024 EPS Estimates for Zymeworks Lifted by Leerink Partnrs - MarketBeat

Nov 11, 2024
pulisher
Nov 09, 2024

Analysts Update Their Estimates For Zymeworks BC Inc - Stocks Register

Nov 09, 2024
pulisher
Nov 09, 2024

Q4 Earnings Estimate for Zymeworks Issued By Leerink Partnrs - Defense World

Nov 09, 2024
pulisher
Nov 09, 2024

Zymeworks (NYSE:ZYME) Raised to Strong-Buy at Leerink Partnrs - Defense World

Nov 09, 2024
pulisher
Nov 08, 2024

Leerink Partnrs Forecasts Zymeworks' Q4 Earnings (NYSE:ZYME) - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Zymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Optimistic Investors Push Zymeworks Inc. (NASDAQ:ZYME) Shares Up 34% But Growth Is Lacking - Simply Wall St

Nov 08, 2024
pulisher
Nov 08, 2024

Zymeworks (NYSE:ZYME) Upgraded to "Strong-Buy" at Leerink Partnrs - MarketBeat

Nov 08, 2024
pulisher
Nov 07, 2024

Leerink lifts Zymeworks stock target on pipeline progress By Investing.com - Investing.com Nigeria

Nov 07, 2024
pulisher
Nov 07, 2024

Leerink lifts Zymeworks stock target on pipeline progress - Investing.com

Nov 07, 2024
pulisher
Nov 06, 2024

Zymeworks doses first subject in Phase I trial of ZW191 for solid tumours - Clinical Trials Arena

Nov 06, 2024
pulisher
Nov 06, 2024

Citigroup Increases Zymeworks (NYSE:ZYME) Price Target to $18.00 - Defense World

Nov 06, 2024
pulisher
Nov 05, 2024

Zymeworks Announces First Patient Dosed in Phase 1 Clinical - GlobeNewswire

Nov 05, 2024
pulisher
Nov 05, 2024

Zymeworks Launches Phase 1 Trial for ZW191 - TipRanks

Nov 05, 2024

Zymeworks Inc. (ZYME) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
大文字化:     |  ボリューム (24 時間):